Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Novel therapies targeting the innate immune system in MDS

Alan List • 15 Jun 2019
EHA 2019
Myelodysplastic Syndromes Azacitidine Ibrutinib

Alan List, MD, from the Moffitt Cancer Center, Tampa, FL, talks about new therapies that have the potential to target the innate immune system in myelodysplastic syndromes (MDS). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Alan List

Inflammation, immune dysregulation and targeting in MDS
Alan List et al. • 24 Jul 2022
1:14
Horizon scan of MDS treatments
Alan List • 5 Mar 2020
0:54
HMAs are the standard, what are their limitations?
Alan List • 5 Mar 2020
1:02
The stages and treatments for myelodysplastic syndromes
Alan List • 5 Mar 2020

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals